Anne Sibille's research while affiliated with Centre Hospitalier Universitaire de Liège and other places

... ML with delta radiomics outperforms single-time-point radiomics in predicting outcomes, promising improved clinical decision-making [31]. However, there is a growing interest in "Delta radiomics," which involves analyzing features changes over time (longitudinal) to predict outcomes [32][33][34][35][36][37][38][39][40][41] with increased robustness compared to single time-point radiomics features [42,43]. Delta radiomics also is favored due to routine imaging in cancer diagnosis and follow-up, promoting its utilization in clinical settings [44]. ...

... Data from the PACIFIC-R observational study indicate that trial-level outcomes from consolidation durvalumab translate to real-world settings with numerically higher percentage of patients alive at 2 years (71.2% vs. 66.3%) and median real-world PFS (21.7 vs. 16.9 months) relative to the pivotal trial. 76,85 Moreover, similar to previous systemic therapies approved in earlier settings, new classes of agents recently approved for treatment of advanced disease, such as antibody-drug conjugates and bispecific antibodies, [86][87][88] hold the potential to further improve the outlook of early and locally advanced NSCLC. ...

... In addition, this line has been used in a phase I clinical trial (GeniusVac-Mel4, NCT01863108) to treat nine patients with metastatic melanoma, with recently published results demonstrating the safety and biological efficacy of this therapeutic vaccine (25). A new trial in lung cancer is ongoing to treat 64 patients, in combination with immune checkpoint blockers (NCT03970746), with recent results confirming its safety and biological activity (26,27). This allogenic approach can be rapidly implemented, and this strategy could cover carriers of the HLA-A*02:01 allele, which is used for presentation of Ags of interest by PDC*line (around 45% of the Caucasian population). ...

... BMS-986012 is a monoclonal antibody against fucosyl-GM1 that is currently being tested in a phase 1/2 SCLC clinical trial (NCT04702880). Previous studies with this antibody have shown a good tolerability profile and promising results in combination with the ICI nivolumab [122]. ...

... More importantly, few studies evaluating the systemic inflammation/nutritional status addressed the issue of the treatment choice in patients suffering from an NSCLC with PD-L1 TPS ≥50%, as these can be treated either with ICI in monotherapy or with ICI + CT [18]. Currently, in these cases, physicians rely on clinical and/or pathological/molecular characteristics to choose between the two treatment modalities [62]. Recently, a study reported that, in contrast to ICI in monotherapy, the ALI score was less associated with outcomes in a cohort of 444 patients treated with CT alone and lost its predictive power in a cohort of 212 patients treated with ICI + CT, raising the question of whether it would be ICI-specific [27]. ...

... 48 There is clinical evidence suggesting that eosinophilia is associated with a favorable prognosis in patients with advanced NSCLC treated with immune checkpoint inhibitors, but the mechanism by which it exerts its influence needs further investigation. 49 ScRNAseq results showed that neutrophils were enriched to a greater extent in nLung lung tissues than that in GGNs, 17 and eosinophils were infiltrated to a higher extent in GGNs than that in SNs. 23 It is difficult to see the therapeutic value of granulocytes in GGNs with these preliminary studies. ...

... With regard to cancer patients, literature data showed both a higher risk of contracting the infection and a higher risk of developing complications of the disease, especially for those with active disease and undergoing treatment (Liang et al., 2020;Yu et al., 2020). More than 30% of cancer patients during the first peak of the pandemic were more worried about COVID-19 than cancer and adopted all suggested preventive measures to avoid infection (Onesti et al., 2021b). Cancer patients were conscious to be at greater risk of complications and death, but disagreed with the possibility of either discontinuing or changing treatment protocols (Onesti et al., 2021b). ...

... The efficacy outcomes seen in our study do not appear to be inferior to the PACIFIC study outcomes, an important finding for real-world evidence, although we were only able to estimate the values, which leaves room for uncertainty. That said, our findings show improved outcomes compared to historical data, but less benefit than what other real-world analyses have found [4,9]. In the PACIFIC-R study, the median rwPFS was 21.7 mo while the mOS was still not met, with an estimation of 70% of the population being alive in 2 years. ...

... The increase in NLR [95][96][97], myeloid-to-lymphoid ratio (M:L), absoluteneutrophil-count-to-absolute-lymphocyte-count ratio (ANC:ALC) and absolute neutrophil counts (post-ANCs) is associated with lower PFS [98] and OS [99]. Conversely, low plateletto-lymphocyte ratio (PLR) [96,100], monocyte-to-lymphocyte ratio (MLR) [96], and high rates of ALC [101], absolute eosinophil count (AEC) [102], and relative eosinophil count (REC) [103] are associated with better PFS. ...

... Of the lung cancers diagnosed, around 71% were diagnosed at stage I and approximately 8% at stages IIIb-IV, and 51.2% were adenocarcinomas, thus demonstrating that, unlike other comparable trials, the NELSON trial screen-detected lung cancers are more often diagnosed at stage I and less frequently at stages IIIb-IV. However, it was suggested that the screening strategy of the NELSON trial results in a favorable diagnosis [46] with a reduction in mortality from lung cancer [47]. Still, the complete consensus for a systematic lung cancer screening is yet to be attained [47]. ...